DOCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Doximity Inc (DOCS) is not a strong buy for a beginner, long-term investor at this time. The stock's technical indicators are mixed, with bearish moving averages and neutral RSI, while the financial performance shows declining net income and EPS despite revenue growth. Analysts' ratings are mixed, with some optimism for the long-term but concerns about near-term headwinds. Options data suggests a bullish sentiment, but it is not strong enough to override the broader concerns. Given the lack of immediate positive catalysts and the user's preference for long-term investments, holding off on buying is recommended.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 51.061. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 25.293 with key resistance at 26.653 and support at 23.933.
Analysts like Piper Sandler and Canaccord see long-term potential in Doximity's AI tools and believe the current sell-off is an overreaction. Revenue grew 9.76% YoY in Q3 2026, showing some growth momentum.
Net income dropped by 18.14% YoY, and EPS fell by 16.22% YoY. Gross margin also declined slightly. Analysts have lowered price targets significantly, citing near-term headwinds and regulatory uncertainties. The stock's technical indicators show bearish trends, and there is no recent news or congress trading data to provide a positive catalyst.
In Q3 2026, revenue increased by 9.76% YoY to $185.05M. However, net income dropped by 18.14% YoY to $61.56M, and EPS fell by 16.22% YoY to 0.31. Gross margin also declined slightly to 89.89%, down 1.86% YoY.
Analysts are mixed on Doximity. Piper Sandler raised its price target to $42, citing the potential of Doximity's AI tools, while others like JPMorgan and Goldman Sachs lowered their price targets, citing near-term headwinds. The average sentiment is cautiously optimistic for the long term but bearish for the short term.
